Stanford Develops Experimental Nasal Spray Aiming to Protect Against Multiple Respiratory Infections

ଖେଳ

ୟୁଏସ୍‌ ଓପନ୍‌ରେ ଭାରତକୁ ଝଟକା: ଭାମ୍ବ୍ରି-ଚନ୍ଦ୍ରଶେଖର ବିଦା, ଦ୍ୱିତୀୟ ରାଉଣ୍ଡରେ...

September 06, 2026

US Open Day 8: ସାବାଲେଙ୍କା-ଆଲକାରାଜଙ୍କ ଉପରେ ନଜର, କ୍ୱାର୍ଟର...

September 06, 2026

MS ଧୋନିଙ୍କ IPL ଭବିଷ୍ୟତ ନେଇ ବଡ଼ ଖୁଲାସା, କ’ଣ...

September 05, 2026

ଡ୍ରେସିଂ ରୁମ୍‌ ବ୍ୟବହାରକୁ ନେଇ ଚିନ୍ତା: ରିଜୱାନ୍ ଓ ଇମାମ୍‌ଙ୍କୁ...

September 05, 2026

ଅପରାଧ

ଗୋଟିଏ ଦିନରେ ଓଡ଼ିଶାରେ ୩ ଦୁଷ୍କର୍ମ ଅଭିଯୋଗ; ପୀଡ଼ିତାଙ୍କ ମଧ୍ୟରେ...

September 05, 2026

ବାଲେଶ୍ୱରରେ ସାମାନ୍ୟ କଥାକୁ ନେଇ ବିବାଦ: କାଠ ଫାଳିଆରେ ଆକ୍ରମଣ,...

September 05, 2026

ଭୁବନେଶ୍ୱର ମନ୍ଦିରରୁ ମା’ ବୁଢ଼ୀ ଠାକୁରାଣୀଙ୍କ ମୂର୍ତ୍ତି ଚୋରି; ବର୍ଷକରେ...

September 05, 2026

Stanford Develops Experimental Nasal Spray Aiming to Protect Against Multiple Respiratory Infections

Researchers at Stanford University are testing a nasal spray that may offer broad protection against viruses, bacteria, and even allergies. Human trials are needed to confirm its safety and effectiveness.

Published by Somesh | February 20, 2026

Stanford University researchers in the US are developing an experimental nasal spray designed to provide wide-ranging protection against respiratory illnesses, including common colds, flu, and dangerous bacterial infections. Unlike traditional vaccines, which target a specific pathogen, this “universal vaccine” primes the lungs’ immune cells to respond rapidly to almost any invading virus or bacterium. Animal studies have shown that the spray boosts lung macrophages, putting them on “amber alert,” and reduces viral infections by 100–1,000 times over three months. It also showed promise against antibiotic-resistant bacteria likeStaphylococcus aureusandAcinetobacter baumannii.

Experts caution that these results are preliminary, as human immune systems differ from mice, and keeping immune cells constantly alert carries potential risks of inflammation or tissue damage. Clinical trials are being planned to test both safety and effectiveness in humans. Researchers envision the spray as a complement to conventional vaccines rather than a replacement, potentially offering protection at the start of pandemic outbreaks or seasonal respiratory surges.

If human trials are successful, the once-a-season nasal spray could revolutionise respiratory disease prevention, providing temporary but broad protection to millions while pathogen-specific vaccines are developed. For now, the approach remains experimental, but it represents a dramatic shift in vaccine science and could pave the way for a new era of universal respiratory protection.